Post

New research · Ophthalmology
Immunity, inflammation and disease · 14h
Cohort studyImmunity, inflammation and disease · 2026

Impact of Early COVID-19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database.

Hou-Ting Kuo, Alan Y Hsu, De-Yi Liu … Yi-Yu Tsai
Read paper
OphthalmologyCohort study

Early COVID-19 antiviral therapy associated with lower risk of new-onset uveitis.

Impact of Early COVID-19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database.

Hou-Ting Kuo … Yi-Yu Tsai
Immunity, inflammation and disease · 2026
Purpose

To assess whether antivirals are associated with a reduced incidence of uveitis following COVID-19.

Methods

Who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir) within 5 days of diagnosis were matched 1:1 with untreated controls using propensity score matching.

n = 438,455 patients
Results

early antiviral treatment lowered the chance of developing new eye inflammation

HR by subgroup · 95% CI
null = 1
uveitis at 3 months
0.62
6 months
0.68
1 year
0.76
3 years
0.80
all duration
0.81
More results

Subgroup analysis revealed consistent benefit across all age groups, with females experiencing greater protection than males.

Significant reductions in uveitis risk were observed among patients with diabetes (HR = 0.68, 95% CI: 0.52-0.89), hyperlipidemia (HR = 0.78, 95% CI: 0.65-0.95), and heart failure (HR = 0.52, 95% CI: 0.30-0.90).

More results

Among the antivirals, Paxlovid was associated with a significant risk reduction (HR = 0.83, 95% CI: 0.71-0.96), whereas Molnupiravir and Remdesivir showed no statistically significant effect.

Besides, the risk reduction was evident regardless of prior COVID-19 vaccination status.

“
Conclusion · 1 of 2

Early antiviral treatment for COVID-19 such as Paxlovid, is associated with a reduced risk of uveitis.

Conclusion · 2 of 2

These findings suggest that, in addition to mitigating systemic disease progression, antiviral therapy may confer ocular protective effects, which could be especially meaningful for high-risk populations.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment